(0.07%) 5 472.99 points
(0.11%) 39 155 points
(0.38%) 17 784 points
(0.10%) $80.91
(-3.66%) $2.66
(-0.77%) $2 312.80
(0.23%) $28.94
(3.64%) $1 022.30
(0.29%) $0.936
(0.69%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer...
Stats | |
---|---|
今日成交量 | 19.39M |
平均成交量 | 1.63M |
市值 | 43.15B |
EPS | $-1.150 ( Q3 | 2023-11-01 ) |
下一个收益日期 | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-57.19 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.424 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-14 | Baker Bros. Advisors Lp | Sell | 42 977 301 | Common Stock |
2023-12-14 | Baker Bros. Advisors Lp | Sell | 8 750 | Stock Options (right to buy) |
2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 44 783 214 |
音量 相关性
Seattle Genetics Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Seattle Genetics Inc 相关性 - 货币/商品
Seattle Genetics Inc 财务报表
Annual | 2022 |
营收: | $1.96B |
毛利润: | $1.55B (79.10 %) |
EPS: | $-3.30 |
FY | 2022 |
营收: | $1.96B |
毛利润: | $1.55B (79.10 %) |
EPS: | $-3.30 |
FY | 2021 |
营收: | $1.57B |
毛利润: | $1.26B (80.21 %) |
EPS: | $-3.70 |
FY | 2020 |
营收: | $2.18B |
毛利润: | $1.96B (89.99 %) |
EPS: | $3.51 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Seattle Genetics Inc
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。